Featured Studies Results
Study Type: Treatment

Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
Clinicaltrials.gov identifier:
NCT06545942
Treatment
Treatment study for people with advanced or metastatic cancers

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer
Clinicaltrials.gov identifier:
NCT05498272
Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling
Treatment
Men aged 18 years or older with metastatic prostate cancer

New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT06022029
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas

High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation
Clinicaltrials.gov identifier:
NCT05011383
Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation

Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)
Treatment
Hispanic and Latino people diagnosed with colorectal cancer

Nipple Sparing Mastectomy With Immediate Implant-Based Reconstruction for Women With Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT05720039
Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Clinicaltrials.gov identifier:
NCT04030559
Treatment
High-risk localized prostate cancer

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
Clinicaltrials.gov identifier:
NCT04550494
Treatment
Treatment study for people with advanced solid tumors

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Clinicaltrials.gov identifier:
NCT04042831
Treatment
Treatment study for people diagnosed with metastatic biliary tract (bile duct) cancer and who have an inherited or tumor mutation in ATM, BRCA 1/2, BRIP1, CHEK2, RAD51C, RAD51D, PALB2, PTEN, NBN and others
If you would like a more in-depth search, visit our In-Depth Search Tool that searches for studies in FORCE’s database and in clinicaltrials.gov